NEW YORK (GenomeWeb News) — Sequenom today said it has exclusively licensed IP to a non-invasive prenatal genetic analysis technology from the Chinese University of Hong Kong.
 
Under the agreement, Sequenom may use the school’s methylation marker and gene expression-analysis IP for fetal nucleic acids in North America, Europe, Australia, and Japan. It also received non-exclusive rights in China.
 
Sequenom also said the deal includes rights to some methylation and nucleic acid markers.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.